Navigation Links
Which Prostate Cancers Really Need Treatment?
Date:7/9/2013

MIAMI, July 9, 2013 /PRNewswire-iReach/ -- Urologyweb.com, a leading website from Dr. Bert Vorstman, has recently posted a new article outlining which prostate cancers really need treatment.

"Most prostate cancers diagnosed are classed as the low or favorable-risk Gleason 6 (3+3) prostate cancer and the majority of these cancers behave like insignificant pseudo cancers, do not progress and do not need any treatment whether through focal therapy or whole gland treatment. 

"These cancers should simply be monitored through active surveillance", said Dr Vorstman, a Coral Springs Florida urologistwith over 30 years of experience in managing localized prostate cancer. In addition, Dr Vorstman warned that, "For many men, their road to debilitation and zero benefits began with the highly unreliable PSA prostate cancer screening blood test followed by the risky and painful office prostate biopsy. The finding of some insignificant prostate cancer was then license for misinformation, misrepresentation and falsehoods culminating in mismanagement and mistreatment. In fact, the risk of Gleason 6 (3+3) treatment harm is greater than the risk of the untreated insignificant prostate cancer." Dr Vorstman added, "Particularly disturbing is the gross overtreatment of most of these Gleason 6 (3+3) prostate cancers with the toxic, irreversible radical surgery/robotic prostatectomy for which there is no evidence based medicine support. This unproven, emasculating radical surgery/robotic prostatectomy for insignificant Gleason 6 (3+3) cancers represents "modern day" human experimentation. 

"At 20 years, these patients, or "sufferers" are survivors of their treatment, not survivors of their insignificant cancer." Furthermore said Dr Vorstman, "The gross overdiagnosis and overtreatment of this non aggressive prostate cancer and the insignificant number of lives saved by the crippling surgical treatment have been underscored by the embarrassing USPSTF report on prostate cancer screening as well as the flurry of class action lawsuits against the robot equipment makers. In response to these concerns there have been some moves by urologists to readdress prostate cancer screening guidelines and to tighten the indications for the use of the highly unreliable PSA blood test (the AUA now suggesting greatest evidence for "benefit" from routine screening was for men ages 55 to 69 only) as well as address the burning issue of prostate cancer overdiagnosis. Regrettably though, concerns regarding the pervasive overtreatment of insignificant Gleason 6 (3+3) prostate cancer with the irreversible, unproven, high-risk robotic prostatectomy are not being addressed."

Dr Vorstman's passion is the empowerment of men and their wives/partners about localized prostate cancer, management options and health choices. He is a dedicated patient advocate and an outspoken critic of overdiagnosis and overtreatment of the favorable-risk Gleason 6 (3+3) prostate cancer. His powerful messages and insights about prostate cancer reach many people through his website and blog, www.urologyweb.com

To review Dr Vorstman's extensive writings on localized prostate cancer management go to http://www.urologyweb.com/exclusive-medical-reports/or, contact Dr Bert Vorstman at 877 783 4438 or, bvorstmanmd@gmail.com

Media Contact: Dr. Bert Vorstman, UrologyWeb, 954-752-3166, bvorstmanmd@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Urologyweb.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
2. Which plants will survive droughts, climate change?
3. Scientists uncover mechanism by which plants inherit epigenetic modifications
4. CSHL-led team discovers new way in which plants control flower production
5. Researchers identify proteins that indicate which kidney tumors are most likely to spread
6. Gladstone scientists discover novel mechanism by which calorie restriction influences longevity
7. Which nutritional factors help preserve muscle mass, strength and performance in seniors?
8. Video study shows which fish clean up coral reefs, showing importance of biodiversity
9. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
10. Scientists sequence genome of sacred lotus, which likely holds anti-aging secrets
11. Mechanism discovered which aids Legionella to camouflage itself in the organism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology: